United Therapeutics Shares Thrive [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
Its Tyvaso medicine should benefit from a regulatory approval delay for a competing drug, leaving UTHR without direct competition to hinder its business development efforts. Financially, the company's second-quarter performance featured revenue growth of almost 20% and per-share earnings growth of 12%. UTHR's pipeline is promising too. Analysts suggest the commercialization of new therapies could generate 50% returns or more in the next few years. It's no wonder UTHR shares are up 64% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock. United Therapeutics Under Heavy Accumulation Institutional volumes reveal plenty. Recently, UTHR has enjoyed strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in UTHR shares. They reflect our proprietary inflow signal, pushing the stock higher: Plenty of health care names are under accumu
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- Manchester gets offer from United Therapeutics to buy nearly 350 acres in Hacket Hill area [Yahoo! Finance]Yahoo! Finance
- United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual MeetingBusiness Wire
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Jefferies Financial Group Inc. from $315.00 to $432.00. They now have a "buy" rating on the stock.MarketBeat
- Trans+ employees are not alone in bearing the burden of bigotry—it costs employers, too [Fortune]Fortune
- United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—EverBusiness Wire
UTHR
Earnings
- 7/31/24 - Miss
UTHR
Sec Filings
- 9/24/24 - Form 4
- 9/23/24 - Form 4
- 9/23/24 - Form 144
- UTHR's page on the SEC website